135262-85-0

Usage

Uses

Used in Pharmaceutical Industry:
Carbamic acid, 3-cyclohexen-1-yl-, 1,1-dimethylethyl ester (9CI) is used as a chemical intermediate for the synthesis of various medications. Its application in this industry is primarily due to its role in the development of drugs for the treatment of cancer and other serious medical conditions. Carbamic acid, 3-cyclohexen-1-yl-, 1,1-dimethylethyl ester (9CI)'s unique chemical structure and properties make it a valuable component in the creation of effective pharmaceuticals.
As a potential teratogen, it is crucial to handle and store Carbamic acid, 3-cyclohexen-1-yl-, 1,1-dimethylethyl ester (9CI) with proper safety measures to prevent any adverse effects on human health, particularly during pregnancy. This includes following guidelines for proper storage, handling, and disposal to minimize the risk of exposure to this hazardous compound.

Upstream product

• 210574-42-8 (±)-tert-butyl octa-1,7-dien-4-ylcarbamate 
• 77626-69-8 cyclohex-3-enecarboxylic acid allyl ester 
• 75-65-0 tert-butyl alcohol 
• 4771-80-6 1,2,5,6-tetrahydrobenzoic acid 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27489-62-9 trans-4-hydroxycyclohexylamine 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 1204401-31-9 tert-butyl cis-4-(iodo)cyclohexylcarbamate 
• 130309-46-5 trans-4-(tert-butoxycarbonylamino)cyclohexane carboxylic acid 
• 124-63-0 methanesulfonyl chloride 
• 72581-32-9 cyclohex-3-enylmethanol 
• 4103-88-2 1-isocyano-3-cyclohexene 
• 4129-17-3 diphenylphosphoranyl azide 
• 4248-19-5 tert-butyl carbazate 

Downstream Products

• 1061338-33-7 N-Ethyl-N-(cyclohex-3-enyl)-carbamic acid tert-butyl ester 
• 22615-33-4 cyclohex-3-en-1-ylamine hydrochloride 
• 836607-81-9 (1RS,2SR,4SR)-2-bromo-7-azabicyclo[2.2.1]heptane 
• 1061341-34-1 tert-butyl allyl(cyclohex-3-enyl)carbamate 
• 422507-09-3 4-[N-benzyl-N-(tert-butoxycarbonyl)amino]cyclohex-1-ene 
• 1195100-55-0 tert-butyl (6-chloropyridin-3-yl)methyl(cyclohex-3-enyl)carbamate 

Relevant academic research and scientific papers

Merging Halogen-Atom Transfer (XAT) and Cobalt Catalysis to Override E2-Selectivity in the Elimination of Alkyl Halides: A Mild Route towardcontra-Thermodynamic Olefins

We report here a mechanistically distinct tactic to carry E2-type eliminations on alkyl halides. This strategy exploits the interplay of α-aminoalkyl radical-mediated halogen-atom transfer (XAT) with desaturative cobalt catalysis. The methodology is high-yielding, tolerates many functionalities, and was used to access industrially relevant materials. In contrast to thermal E2 eliminations where unsymmetrical substrates give regioisomeric mixtures, this approach enables, by fine-tuning of the electronic and steric properties of the cobalt catalyst, to obtain high olefin positional selectivity. This unprecedented mechanistic feature has allowed access tocontra-thermodynamic olefins, elusive by E2 eliminations.

Photoredox/Cobalt Dual-Catalyzed Decarboxylative Elimination of Carboxylic Acids: Development and Mechanistic Insight

Recently, dual-catalytic strategies towards the decarboxylative elimination of carboxylic acids have gained attention. Our lab previously reported a photoredox/cobaloxime dual catalytic method that allows the synthesis of enamides and enecarbamates directly from N-acyl amino acids and avoids the use of any stoichiometric reagents. Further development, detailed herein, has improved upon this transformation's utility and further experimentation has provided new insights into the reaction mechanism. These new developments and insights are anticipated to aid in the expansion of photoredox/cobalt dual-catalytic systems.

Preparation method of beta-homoglutamic acid

The invention belongs to the field of preparation of organic compounds, and provides a preparation method of beta-homoglutamic acid. The method is characterized in that: 3-cyclohexenecarboxylic acid is used as a raw material, beta-homoglutamic acid is synthesized at a high yield through three the steps of reactions of Curtius rearrangement, olefin oxidation and protection group removal, and beta-homoglutamic acid with high yield and high optical purity can be obtained through configuration retention by using optically pure 3-cyclohexenecarboxylic acid. The method has the advantages of easily available raw materials, mild reaction conditions and low cost, and is suitable for large-scale preparation of beta-homoglutamic acid.

Inhibition of serine and proline racemases by substrate-product analogues

d-Amino acids can play important roles as specific biosynthetic building blocks required by organisms or act as regulatory molecules. Consequently, amino acid racemases that catalyze the formation of d-amino acids are potential therapeutic targets. Serine racemase catalyzes the reversible formation of d-serine (a modulator of neurotransmission) from l-serine, while proline racemase (an essential enzymatic and mitogenic protein in trypanosomes) catalyzes the reversible conversion of l-proline to d-proline. We show the substrate-product analogue α-(hydroxymethyl)serine is a modest, linear mixed-type inhibitor of serine racemase from Schizosaccharomyces pombe (K i = 167 ± 21 mM, Ki′ = 661 ± 81 mM, cf. Km = 19 ± 2 mM). The bicyclic substrate-product analogue of proline, 7-azabicyclo[2.2.1]heptan-7-ium-1-carboxylate is a weak inhibitor of proline racemase from Clostridium sticklandii, giving only 29% inhibition at 142.5 mM. However, the more flexible bicyclic substrate-product analogue tetrahydro-1H-pyrrolizine-7a(5H)-carboxylate is a noncompetitive inhibitor of proline racemase from C. sticklandii (Ki = 111 ± 15 mM, cf. Km = 5.7 ± 0.5 mM). These results suggest that substrate-product analogue inhibitors of racemases may only be effective when the active site is capacious and/or plastic, or when the inhibitor is sufficiently flexible.

Palladium- and ruthenium-catalyzed cycloisomerization of enynamides and enynhydrazides: A rapid approach to diverse azacyclic frameworks

I want to ride my azacycle: The title reaction of enynamides affords a wide diversity of azacycles. The reactions are high-yielding, highly stereoselective, and proceed rapidly under mild reaction conditions. Equivalent transformations using enynhydrazides offer new routes to pyrazole and indazole scaffolds. Boc=tert-butoxycarbonyl, EWG=electron-withdrawing group, Ns=4-nitrobenzenesulfonyl, Ts=4-toluenesulfonyl. Copyright

PROCESS FOR THE PREPARATION OF PLEUROMUTILINS

Process for the preparation of a Compound of formula I in the form of a single stereoisomer in crystalline form, comprising deprotecting the amine group in a Compound of formula IIa or in a mixture of a compound of formula IIa With a compound of formula IIb and isolating a Compound of formula I from the reaction mixture; Compounds and salts of Compounds of formula I in crystalline form; pharmaceutical compositions comprising such salts; processes for the preparation of intermediates and intermediates in a process for the preparation of a Compound of formula I.

A simple and efficient synthesis of N-substituted cyclohex-3-enamines

A straightforward preparation of N-substituted cyclohex-3-enamines starting from the commercially available trans-4-aminocyclohexanol hydrochloride is described. Cyclohex-3-enamino-functionalized compounds have proven to be interesting intermediates in me

Synthesis and transformations of alkyl N-(1-cyclohex-3-enyl)carbamates prepared from cyclohex-3-ene carboxylic acid via Curtius rearrangement

The Curtius rearrangement of cyclohex-3-ene carboxylic acid using diphenylphosphoryl azide in the presence of triethylamime and ethanol, t-butanol or benzyl alcohol has been described. As a result the synthesis of ethyl, t-butyl or benzyl N-(1-cyclohex-3-enyl)carbamates has been achieved in one pot, in good chemical yield. A series of transformations of benzyl N-(1-cyclohex-3-enyl)carbamate, such as iodination and epoxidation, as well as opening of the corresponding ring epoxide, have been carried out leading to some useful oxygenated cyclohexylamimo building blocks.

Diamine derivatives

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.